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Abstract
A systematic literature review was performed evaluating articles examining the effects of pseudoexfoliation 
syndrome (PEX) and glaucoma (PEXG) on the cornea with a focus on the corneal endothelium. We 
searched for articles relevant to pseudoexfoliation syndrome, pseudoexfoliation glaucoma and corneal 
endothelial cell counts using Pubmed, Google Scholar Database, Web of Science and Cochrane Library 
databases published prior to September of 2016. We then screened the references of these retrieved 
papers and performed a Web of Science cited reference search. Corneal characteristics analyzed included 
central corneal thickness (CCT), corneal nerve density, endothelial cell density (ECD), polymegathism, 
and pleomorphism. These parameters were compared in the following populations: control, PEX, PEXG, 
and primary open angle glaucoma (POAG). Over 30 observational studies were reviewed. Most studies 
showed a statistically significant lower ECD in PEX and PEXG populations compared to controls. Overall, 
PEX eyes had a non‑statistically significant trend of lower ECDs compared to PEXG eyes. No consistent 
trends were found when analyzing differences in CCT amongst control, PEX and PEXG groups. For the 
few studies that looked at corneal nerve characteristics, the control groups were found to have statistically 
significantly greater nerve densities than PEX eyes, which had significantly greater densities than PEXG 
eyes. ECD and corneal nerve densities may be potential metrics for risk‑stratifying patients with PEX and 
PEXG. Our literature review provided further evidence of the significant negative influence PEX has on 
the cornea, worsening as patients convert to PEXG.
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The prevalence of PEX over the age of 60 is roughly 
10‑20%,[2] increasing to 40% over the age of 80,[3] and 
is highly dependent on race and ethnicity.[4] PEX is a 
systemic, age related microfibrillopathy characterized 
clinically by the production and deposition of 
extracellular granular material in tissues, most notably 
in the anterior chamber of the eye.[5] The material 
is classically found on the lens capsule, pupillary 
border, the iris, non‑pigmented ciliary epithelium, lens 
zonules, trabecular meshwork and corneal endothelial 
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INTRODUCTION
Pseudoexfoliation syndrome (PEX) is the leading 
cause of secondary open angle glaucoma (OAG).[1] 
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cells. The material has also been demonstrated along 
vascular endothelium, corneal epithelial basement 
membrane and corneal stroma.[5] Although the disease 
is systemic, it can be highly asymmetric, with material 
in the fellow “normal” eye only being identified on 
biopsy in some patients.[6] The ocular pathologies 
resulting from the deposition of this material include 
secondary open angle glaucoma, disturbances of 
the pre‑corneal tear film, zonular weakness and 
dehiscence resulting in phacodonesis, angle closure 
glaucoma and lens dislocation, capsular rupture and 
vitreous release during cataract surgery, poor pupillary 
dilation, blood‑aqueous barrier dysfunction and corneal 
endothelial decompensation.[5]
The rate of conversion from PEX to PEXG is 5% in 
patient with PEX for 5 years, 15% at 10 years[7,8] and 
a 15 year risk of up to 60%.[9] Compared to primary 
open angle glaucoma (POAG), pseudoexfoliation 
glaucoma (PEXG) is more severe; it is associated 
with an elevated risk of blindness, higher intraocular 
pressures (IOP) with higher IOP fluctuations, and 
increased glaucoma medication resistance.[10] The 
mechanism of damage to the high resistance trabecular 
meshwork in PEXG has been shown to be unique to that 
of POAG.[5] Additionally, it is still uncertain if factors 
related to PEX other than IOP elevations influence the 
more severe neuropathy seen in PEXG.[5] Outside of IOP 
measurements, qualitatively determining the amount of 
pseudoexfoliation material at the trabecular meshwork 
and measurements of flare in the anterior chamber,[11] 
no clinical biomarkers are currently used to quantify 
the severity of PEX and PEXG or determine the risk 
of glaucoma development and progression in these 
patients. Determining the frequency of monitoring and 
aggressiveness of treatment in this patient population 
can be challenging. Recent literature has suggested the 
use of corneal parameters as an adjunct measurement in 
managing patients with PEX.[12‑14]
Several studies have shown the influence of PEX 
on the cornea, specifically the corneal endothelium 
cell density (ECD), with multiple studies showing 
decreased ECDs of patients with PEX and PEXG 
compared to control patients.[13‑36] Additionally, patients 
with PEX were found to have decreased keratocyte 
stromal cell counts, basal corneal epithelial cell counts, 
and sub‑basal neural integrity[13,14,23,36] which has been 
correlated to the decreased corneal sensitivity seen in 
PEX patients.[12,13] However, it is less clear as to whether 
patients with PEXG have more severe corneal alterations 
than PEX alone without secondary glaucoma, or if 
these corneal alterations can be utilized in the clinic to 
help manage patients at risk of developing or already 
with glaucomatous damage associated with PEX. The 
objective of this paper is to review the current literature 
evaluating the influence of PEX on the cornea, and 
determine the potential use of quantifiable corneal 
characteristics as clinical biomarkers to risk‑stratify 
patients with PEX and PEXG.
METHODS
We searched for articles relevant to pseudoexfoliation 
syndrome, pseudoexfoliation glaucoma and corneal 
endothelial cell counts using Pubmed, Google Scholar 
Database, Web of Science and Cochrane Library 
databases published prior to September of 2016. We 
then screened the references of these retrieved papers 
and performed a Web of Science cited reference 
search.
Statistical analyses were not provided for all 
subgroups in some studies. Using means, standard 
deviations, and sample sizes provided by the studies, 
we were able to perform statistical calculations. For the 
cases of non‑paired data, a two‑tailed student’s t‑test 
for equal variance was used. For paired data, a paired 
two‑tailed student’s t‑test was performed.
Devices used in the studies varied between a number 
of specular and confocal microscopes. Both contact and 
non‑contact measurement techniques were used with 
the specular imaging. ECD analysis ranged between 
completely manual analysis involving a standard grid 
placed over developed film with manual counting,[15] 
to fully automatic analysis that relied on the machine 
to provide all the identification and calculations.[23,25] 
ECD was universally reported in units of cell/mm2. 
Measurements of pleomorphism varied. The majority 
of studies reported a percentage of hexagonal cells; 
with a few reporting a percentage of pleomorphism, 
an inversely related parameter. Therefore, these 
measurements were converted to a hexagonal cell 
percentage equivalent using equation 1.
Hexagonality (%) = 100% ‑ Pleomorphism (%) (1)
Polymegathism was quantified most commonly as 
a coefficient of variance in cell area (CV in cell area); 
however, a few studies measured a percentage of 
polymegathism. Since these measurements were directly 
related we chose not to convert these values. Central 
corneal thickness (CCT) was provided in micrometers 
in most studies. Our search did not include studies 
specifically focusing on CCT associations with PEX or 
PEXG, but we evaluated this data if present in the studies.
Four studies looked at corneal nerve parameters. 
They used a variety of different terminology to 
describe similar concepts. We standardized the 
terminology to long nerve fiber density (LNFD), nerve 
branch density (NBD), total nerve density (TND), and 
tortuosity. Long nerve fiber density was defined as 
number of major nerves (or long nerve fiber bundles) per 
square millimeter. Nerve branch density was defined as 
the number of long nerves and their branches per square 
millimeter. Total nerve density was defined as length of 
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nerve fiber in millimeters per square millimeter.[23] Both 
studies that looked at tortuosity used similar scales, 
one of which[36] specifically used the Oliveira‑Soto and 
Efron scale outlined below which grades tortuosity 
from 0 to 4.[37]
 Grade 0: nearly straight
 Grade 1: slightly tortuous
 Grade 2: moderately tortuous with numerous changes 
in the direction of the fiber
 Grade 3: very tortuous
 Grade 4: extremely tortuous with significant 
convolutions throughout their course.
RESULTS
We identified 30 studies that measured either endothelial 
cell density, polymegathism, pleomorphism, corneal 
nerve density, or CCT, and compared these values 
in patients with PEX and PEXG against a control 
group.[13‑36,38‑43] Six of these were published in a language 
other than English.[18,21,40‑43] One study was published as 
an abstract only.[39]
Of the 23 articles analyzed, [Supplementary Table 1], 
we found only observational studies—case‑control, 
case‑series, cross‑sectional and cohort studies. Control 
groups mostly consisted of healthy patients with no 
ocular disease; a few studies also used patients with 
senile cataracts, or unaffected fellow eyes. For the PEX 
and PEXG groups, most studies excluded patients with 
prior ocular surgery or other ocular pathology. Eight 
of these studies drew from a patient population with 
senile cataracts undergoing cataract surgery. Seven 
studies: Demircan et al,[17] Hayashi et al,[38] Kaljurand 
et al,[20] Quiroga et al,[27] Tomaszewsk et al,[30] Wali 
et al,[32] and Wirbelauer et al,[35] measured ECD in PEX 
patients and control patients before and after surgery. 
Ostern et al[25] measured ECD only after surgery. We 
further characterized the disease groups in all of these 
studies by the presence of both pseudoexfoliation 
and glaucoma. Not every study reviewed took the 
presence of glaucoma into account. Therefore, we 
categorized disease groups into pseudoexfoliation 
without glaucoma (PEX only), PEXG, patients 
with pseudoexfoliation with unspecified glaucoma 
status (PEX combined), and patients with only POAG. 
Furthermore, studies varied in if they chose patients 
affected by unilateral or bilateral disease. Several 
studies included only patients with unilateral disease 
and compared the diseased eye with the unaffected 
fellow eye.
Table 1 summarizes the corneal endothelial data 
comparing patients with PEX combined against normal 
controls. All studies showed lower ECD values in 
patients with PEX combined; 9 of the 11 reached statistical 
significance. Romero et al[28] performed their analysis in 
stratified age groups (60‑69, 70‑79 and >80). They found 
statistically significant lower values in PEX combined 
patients in the two latter age groups (70‑79 and >80). In 
the 60‑69 group they saw a trend towards lower ECD 
in PEX combined, but without statistical significance. 
They did not provide data for a group that included all 
ages studied. Romero et al[28] was also the only study 
to demonstrate statistically significant increases in 
polymegathism and polymorphism compared to control.
Table 2 summarizes similar data comparing patients 
with PEX only (without glaucoma) against normal 
controls. All studies showed lower ECD in the PEX 
only groups; 10 of the 13 studies reached statistical 
significance. There were stronger trends to higher values 
of pleomorphism (6 of 11 statistically significant) and 
polymegathism (5 of 11 statistically significant) in the 
PEX only group.
Table 3 summarizes corneal endothelial data of 
patients with unilateral PEX. Compared to the fellow 
unaffected eye, the eyes with PEX showed no clear 
differences in any of the corneal parameters. However, 
all four studies that compared clinically unaffected 
fellow eyes to control eyes measured a lower ECD in 
the unaffected fellow eye (2 of the 4 reaching statistical 
significance).
Table 4 summarizes corneal endothelial cell data 
comparing patients suffering from PEXG against PEX 
only. All studies demonstrated a trend towards lower 
ECD in PEXG patients versus PEX only. However, 
only 1 of 10 studies reached statistical significance. 
Average sample sizes for these groups were 31 ± 24 
eyes and 26 ± 18 eyes in the PEX only and PEXG groups, 
respectively. There were trends toward increased 
polymegathism and pleomorphism in PEXG patients. 
In Brooks et al,[15] two patients with bilateral PEX had 
elevated IOPs in only one eye. When comparing these 
PEX eyes to the fellow PEXG eye, they saw lower ECDs 
and less regular cells.
Table 5 summarizes the corneal endothelial data 
comparing patients with PEXG against POAG, showing 
no clear trend regarding the corneal parameters. Ostern 
et al[44] found slightly higher ECD values in the PEXG 
group whereas Sarowa et al[45] found higher ECD values 
in the POAG group.
Eleven of the studies measured CCT. This data is 
summarized in Table 6. There was no consistent trend 
as to the influence of PEX or PEXG on CCT. Four studies 
also analyzed corneal nerve parameters, as seen in 
Table 7. In all studies, the nerve parameters in the control 
group showed significantly greater nerve density than 
PEX which was significantly higher than PEXG.
DISCUSSION
Our literature review has consistently shown 
reduced  ECD in  PEX pat ients  wi th  fur ther 
reductions in PEXG patients. In association with 
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decreasing ECD, was increasing pleomorphism 
and polymegathism. Expectedly, polymegathism 
and pleomorphism measurements showed an 
inverse relationship to ECD. Pathophysiologically, 
this agrees with our understanding of the corneal 
endothelial response to damage. As endothelial 
cells are lost, the remaining cells must grow to 
compensate and during this process they lose their 
characteristic hexagonal shape and homogeneous 
size. The trend towards further reduction in ECD as 
patients progress from PEX to PEXG is likely related 
to endothelial damage from both elevated IOP and 
increased PEX severity, as endothelial loss has 
also been shown in patients with POAG.[46] Sarowa 
et al found a statistically significant lower ECD in 
PEXG eyes compared to POAG eyes, suggesting 
that elevated IOP and PEX are likely independent 
factors damaging the endothelium via separate 
mechanisms.[29]
Pseudoexfoliation associated corneal damage is 
likely multifactorial in etiology. Several theories 
exist as to why this endotheliopathy develops, 
including the penetration of pseudoexfoliation material 
towards Descemets membrane breaking the hexagonal 
connections and signaling of the endothelial layer 
and promoting apoptosis,[47,48] hypoxia to the anterior 
chamber with increased antioxidant stress and reduced 
ascorbic acid levels,[49‑53] changes in the blood‑aqueous 
barrier and vascular endothelial dysfunction,[51,54,55] 
compression of endothelial cells from elevated 
IOP,[46] changes in levels of transforming growth 
factors (increased TGF‑α1 and TGF‑β) and ratios of 
MMPs (matrix metalloproteinase) and TIMPs (tissue 
inhibitor of metalloproteinases) promoting matrix 
accumulation in the affected tissues, and changes 
in cytokine/chemokines in the anterior chamber 
and cornea.[56,5] It is possible that similar or other 
unknown mechanisms, beyond IOP elevations, are also 










n 42 42 ECD (cell/mm2) 2533 ± 320 2304 ± 303 <0.05
age 75.7 76.0 Hexagonal % 49.6 ± 8.1 48.0 ± 9.8 NS
CV in cell size 37.7 ± 5.6 38.3 ± 5.8 NS
Hayashi[38] 
(2013)
n 36 36 ECD (cell/mm2) 2748 ± 261 2608 ± 220 <0.05
age 74.6 72.0 ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑
‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑
Inoue[19] 
(2003)
n 30 26 ECD (cell/mm2) 2632 ± 327 2336 ± 383 <0.05
age 77.5 77.9 Hexagonal % 58.9 ± 6.6 58.4 ± 8.1 NS
CV in cell size 0.336 ± 0.041 0.324 ± 0.033 NS
Kaljurand[20] 
(2007)
n 26 29 ECD (cell/mm2) 2594 ± 519 2543 ± 417 NS
age 68.1 73.5 ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑
CV in cell size 24.4 ± 7.6 22.4 ± 5.7 NS
Oltulu[23] 
(2015)
n 20 37 ECD (cell/mm2) 2570 ± 369 2124 ± 346 <0.05
age 67.8 68.7 ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑
 ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑
Ostern[25] 
(2012)
n 101 46 ECD (cell/mm2) 2144 ± 365 2024 ± 371 NS
age 82.3 82.1 Hexagonal %‡ 53.7 ± 10.9 53.6 ± 10.1 NS
Polymegathism 0.445 ± 0.112 0.440 ± 0.130 NS
Romero[28] 
(2011)
n ‑‑ ‑‑ ECD (cell/mm2) Lower in PEX <0.05 in ages >70
age ‑‑ ‑‑ Hexagonal % Lower in PEX <0.05 in ages >70
  CV in cell size Higher in PEX <0.05 in ages >70
Wang[33] 
(2012)
n 20 20 ECD (cell/mm2) 2652 ± 18 2298 ± 239 <0.05
age 69.5 69.1 Hexagonal % 56.1 ± 10.6 54.5 ± 2.8 NS
CV in cell size 36 ± 1.4 34.7 ± 7.1 NS
Wang[34] 
(1999)
n 27 26 ECD (cell/mm2) 2711.4 ± 307.4 2387.1 ± 319.3 <0.05
age 70.1 71.9 Hexagonal % 56.8 ± 8.7 59.5 ± 6.7 NS
CV in cell size 0.34 ± 0.05 0.33 ± 0.04 NS
Wirbelauer[35] 
(1998)
n 25 25 ECD (cell/mm2) 2648 ± 349 2387 ± 266 <0.05
age 77.1 78.0 Hexagonal % 58.2 ± 4.6 61.1 ± 5.6 NS
CV in cell size 0.36 ± 0.03 0.36 ± 0.1 NS
CNT, control; CV, coefficient of variation; ECD, endothelial cell density; PEX, pseudoexfoliation syndrome; NS, not statistically significant 
‡Hexagonal % calculated with equation 1
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responsible for the increased severity of glaucomatous 
damage seen in PEXG relative to POAG.
Although the more severe progression of PEXG 
compared to POAG may be related to higher IOPs with 
larger fluctuations in PEXG eyes, it is still unclear if 
other mechanisms influence damage to the optic nerve 
in PEXG patients. Linner et al found increased nerve 
pallor in PEX patients versus control patients despite 
statistically equal IOP measurements.[57] The optic 
disc surface area in PEX eyes (both with and without 
Table 2. PEX only vs control









n ‑‑* 12 ECD (cell/mm2) Lower in PEX <0.05
age ‑‑ 70 Hexagonal % Lower in PEX Not stated‖




n 60 36 ECD (cell/mm2) 2565.14 ± 270.17 2346.50 ± 256.88 <0.05
age 77.2 76.5 Hexagonal % 57.55 ± 6.8 53.22 ± 6.4 <0.05
 CV in cell size 33.06 ± 4.2 35.41 ± 7.03 <0.05
Inoue[19]  
(2003)
n 30 19 ECD (cell/mm2) 2632 ± 327 2337 ± 407 <0.05†
age 77.5 77.9 Hexagonal % 58.9 ± 6.6 59.0 ± 7.4 NS†
  CV in cell size 0.336 ± 0.041 0.317 ± 0.030 NS†
Kocabeyoglu[14] 
(2016)
n 55 55 ECD (cell/mm2) 2214.1 ± 323.5 2015 ± 443.5 <0.05
age 66.7 67.6 Hexagonal %‡ 53.0 ± 10.5 47.2 ± 13.8 <0.05
   Polymegathism % 38.4 ± 8.2 38.1 ± 11.2 NS
Miyake[22] 
(1989)
n 15 27 ECD (cell/mm2) 3101 ± 304 2669 ± 502 <0.05
age 77.4 76.2 Hexagonal % 64.7 ± 6.5 57.1 ± 7.1 <0.05
  CV in cell size 0.289 ± 0.044 0.339 ± 0.073 <0.05
Ostern[25] 
(2012)
n 88 30 ECD (cell/mm2) 2154 ± 371 2029 ± 405 NS†
age 82.3 82.1 Hexagonal %‡ 54.0 ± 10.9 55.2 ± 9.4 NS†
   Polymegathism % 0.442 ± 0.113 0.452 ± 0.147 NS†
Puska[26] 
(2000)
n 40 40 ECD (cell/mm2) 2870 ± 386 2779 ± 540 NS
age ‑‑ 68.4 Hexagonal % 82.0 ± 5.0 80.5 ± 6.5 NS
   CV in cell size 0.26 ± 0.03 0.25 ± 0.03 NS
Quiroga[27] 
(2010)
n 356 61 ECD (cell/mm2) 2482 ± 384.15 2315 ± 383.7 <0.05
age 70.7 all 
patients
Hexagonal % 57.9 ± ± 56.1 ± 8.3 NS
   CV in cell size 34.4 ± 5.47 33.9 ± 5.5 NS
Sarowa[29] 
(2016)
n 20 20 ECD (cell/mm2) 2511 ± 171.3 2124 ± 116.0 <0.05
age 64.8 71.9 Hexagonal % 59.3 ± 2.227 46.70 ± 6.45 <0.05
   CV in cell size 32.23 ± 2.686 39.05 ± 3.0 <0.05
Tomaszewski[30] 
(2014)
n 84 68 ECD (cell/mm2) 2503 ± 262 2297 ± 359 <0.05
age 76.7 76.5 Hexagonal % ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑
  CV in cell size ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑
Wang[33] 
(2012)
n 20 7 ECD (cell/mm2) 2652 ± 18 2505 ± 284 NS†
age 69.5 69.1 Hexagonal % 56.1 ± 10.6 55.1 ± 19.1 NS†
   CV in cell size 36 ± 1.4 33.4 ± 7.8 NS†
Wang[34] 
(1999)
n 27 18 ECD (cell/mm2) 2711.4 ± 307.4 2416.5 ± 271.1 <0.05
age 70.7 71.9 Hexagonal % 56.8 ± 8.7 ‑‑ ± ‑‑ ‑‑
   CV in cell size 0.34 ± 0.05 ‑‑ ± ‑‑ ‑‑
Yuksel[36] 
(2016)
n 30 30 ECD (cell/mm2) 3073.63 ± 645.49 2592.60 ± 276.36 <0.05
age 64.1 65.8 Hexagonal %‡ 55.7 ± 9.72 47.77 ± 9.82 <0.05
   Polymegathism % 35.10 ± 7.6 41.9 ± 9.10 <0.05
Zheng[13] 
(2011)
n 27 27 ECD (cell/mm2) 2738.7 ± 233.2 2440.7 ± 236.6 <0.05
age 72.7 74.4 Hexagonal % 50.3 ± 6.8 30.5 ± 10.3 <0.05
CV in cell size 30.6 ± 5.6 45.2 ± 8.7 <0.05
CNT, control; CV, coefficient of variation; ECD, endothelial cell density; PEX, pseudoexfoliation syndrome; NS, not statistically significant; 
†P values calculated from provided data ‡Hexagonal % calculated with equation 1 *Control group size not available ‖ P value not stated in 
the paper and no data available for calculations
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glaucoma) has been reported as being smaller compared 
to controls.[58,59] Pulsatile ocular blood flow has been 
shown to be reduced in unilateral PEX compared to 
the unaffected fellow eye,[60] in addition to reduced 
laminar blood flow with progression of PEXG.[61] 
Several studies have linked oxidative stress, thought 
to be more abundant in PEX eyes, to glaucomatous 
progression.[62,49,63,64] More recently, PEX and PEXG eyes 
have been found to have significantly lower posterior 
choroidal thicknesses, thought to be related to increased 
vascular resistance, compared to fellow unaffected eyes 
and healthy control eyes.[65‑70] As we better understand 
the molecular makeup of pseudoexfoliation material 
and its influence on the eye, it will be interesting to 
evaluate its role in glaucomatous optic neuropathy in 
PEX patients.
Brooks et al and Vannas et al were the only studies 
that compared ECD in PEX only eyes to a fellow PEXG 
eye.[15,31] Vannas et al was the only study to attempt 
to correlate ECD with glaucoma severity based on 
visual field defects.[31] Vannas et al was unable to find 
a correlation between ECD and the severity or length 
of treatment in patients with unilateral PEXG, despite 
finding reduced ECDs in PEXG eye in the majority of 
patients. In the 7 patients that were measured with both 
PEX and PEXG in this study, all 7 had lower or equal 
ECD values in the eye with PEXG compared to the eye 
with PEX only. This study, likely lacked the sample size 
and adequate enough glaucoma characterization to show 
correlations between PEXG severity and ECD. Future 
prospective studies examining correlations between 
corneal parameters, such as ECD, lens dislocation and 
PEXG severity should include not only CDRs but visual 
field data and OCT of the optic nerve and retinal nerve 
fiber layer.
PEX has been described as both a unilateral 
entity and as bilateral but highly asymmetric.[71,72] 
PEX is considered a systemic microfibrillinopathy 


















n 19 19 ECD (cell/mm2) ‑‑ ± ‑‑ Lower in PEX ‑‑ <0.5
age 69 69 Hexagonal % ‑‑ ± ‑‑ Lower in PEX ‑‑ Not stated‖
CV in cell size ‑‑ ± ‑‑ Higher in PEX ‑‑ Not stated‖
Miyake[22] 
(1989)
n 27 17 ECD (cell/mm2) 3101 ± 304 2669 ± 502 2847 ± 540 NS NS
age 76.2 74.2 Hexagonal % 64.7 ± 6.5 57.1 ± 7.1 55.3 ± 9.3 <0.05 NS
CV in cell size 0.289 ± 0.044 0.339 ± 0.073 0.343 ± 0.097 <0.05 NS
Omura[24] 
(2014)
n 49 49 ECD (cell/mm2) ‑‑ ± ‑‑ 2442 ± 35 2602 ± 35 ‑‑ <0.05
age 75.1 75.1 ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
Puska[26] 
(2000)
n 40 40 ECD (cell/mm2) ‑‑ ± ‑‑ 2779 ± 540 2870 ± 386 ‑‑ NS
age 68.4 for all 
PEX
Hexagonal % ‑‑ ± ‑‑ 80.5 ± 6.5 82.0 ± 5.0 ‑‑ ‑‑
CV in cell size ‑‑ ± ‑‑ 0.25 ± 0.03 0.26 ± 0.03 ‑‑ NS
Vannas 
[31] (1977)
n 20 20 ECD (cell/mm2) ‑‑ ± ‑‑ 2393.7 ± 316.2 2482.4 ± 370.7 ‑‑ <0.05
age 67.7 67.7 ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
Wang[33] 
(2012)
n 20 5 ECD (cell/mm2) 2652 ± 18 2298 ± 239 2568 ± 172 NS NS
age 69.1 for all 
PEX
Hexagonal % 56.1 ± 10.6 54.5 ± 2.8 59.4 ± 9.9 NS NS
CV in cell size 36 ± 1.4 34.7 ± 7.1 34.6 ± 1.4 NS NS
Wang[34] 
(1999)
n 15 15 ECD (cell/mm2) 2711.4 ± 307.4 2483.9 ± 290.7 2494.6 ± 271.1 <0.05† NS
age 71.9 for all 
PEX
‑‑ 56.8 ± 8.7 ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
‑‑ 0.34 ± 0.05 ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
Zheng[13] 
(2011)
n 27 27 ECD (cell/mm2) 2738.7 ± 233.2 2440.7 ± 236.6 2386.6 ± 200.8 <0.05 NS
age 74.4 for all 
PEX
Hexagonal % 50.3 ± 6.8 30.5 ± 10.3 ‑‑ ± ‑‑ NS NS
CV in cell size 30.6 ± 5.6 45.2 ± 8.7 ‑‑ ± ‑‑ NS ‑‑
CNT, control; CV, coefficient of variation; ECD, endothelial cell density; PEX, pseudoexfoliation syndrome; NS, not statistically significant 
†P values calculated from provided data ‖ P value not stated in the paper and no data to use for calculations
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closely linked to mutations in the lysyl oxidase‑like 
1 (LOXL1) gene,[51] with pseudoexfoliative material 
being found throughout visceral organs in affected 
individuals.[73‑75] Conjunctival biopsies of patients with 
unilateral PEX demonstrated microscopic disease in the 
unaffected fellow eye.[6] Our review of the literature 
has shown that clinically unaffected fellow eyes do 
not have significant differences in ECD compared 
to their paired eyes with PEX, with both showing 
similarly decreased ECD when compared to a group 
of age‑matched controls. The bilateral decrease in ECD 
of these asymmetric PEX eyes supports the theory of 
an asymmetric bilateral process, and provides some 
evidence that the corneal endothelium may be one of 
the earliest intraocular structures with observable (and 
measurable) damage secondary to PEX before the 
presence of pseudoexfoliative material on the lens 
capsule or iris.
While our focus of the literature review was on the 
association between ECD and pseudoexfoliation, many 
papers also provided data evaluating the effect of PEX 
and PEXG on CCT and corneal nerve densities. As 
shown in Table 6, there was no conclusive evidence as 
to the influence PEX alone has on CCT. Two of the 4 
studies showed a statistically significant reduction in 
CCT of patients with PEXG versus PEX, and 1 of the 4 a 
statistically significant increase in CCT in PEXG patients. 
The confounding influence of glaucoma and elevated IOP 
in these patients makes the impact of pseudoexfoliation 
on CCT difficult to interpret. It is possible that the more 
advanced damage to corneal keratocytes seen in the 
PEXG patients compared to PEX patients effects CCT. 
Keratocytes, which help regulate collagen production 
and spacing in the cornea, in addition to extracellular 
matrix (ECM) proteoglycans and glycoaminoglycans, 
which dictate corneal osmotic pressure, may be altered 



















n 60 36 30 ECD (cell/mm2) 2565.14 ± 270.17 2346.50 ± 256.88 <0.05 2246.10 ± 251.83 <0.05 NS
age 77.2 76.5 77.2 Hexagonal % 57.55 ± 6.8 53.22 ± 6.4 <0.05 51.03 ± 6.3 <0.05 NS
 CV in cell size 33.06 ± 4.2 35.41 ± 7.03 <0.05 36.14 ± 6.89 <0.05 NS
Inoue[19] 
(2003)
n 30 19 7 ECD (cell/mm2) 2632 ± 327 2337 ± 407 <0.05† 2332 ± 336 <0.05† NS
age 77.5 77.9 77.9 Hexagonal % 58.9 ± 6.6 59.0 ± 7.4 NS† 56.8 ± 10.2 NS† NS
    CV in cell size 0.336 ± 0.041 0.317 ± 0.030 NS† 0.341 ± 0.038 NS† NS
Ostern[25] (2012) n 88 30 15 ECD (cell/mm2) 2154 ± 371 2029 ± 405 NS† 2012 ± 321 NS† NS
age 82.3 82.1 for all 
PEX
Hexagonal %‡ 54.0 ± 10.9 55.2 ± 9.4 NS† 51.4 ± 11.3 NS† NS†
    Polymegathism % 0.442 ± 0.113 0.452 ± 0.147 NS† 0.419 ± 0.096 NS† NS
Sarowa[29] 
(2016)
n 20 20 20 ECD (cell/mm2) 2511 ± 171.3 2124 ± 116.0 <0.05 2062 ± 121.1 <0.05 NS
age 64.8 71.9 70.6 Hexagonal % 59.3 ± 2.227 46.70 ± 6.45 <0.05 48.25 ± 6.30 <0.05 NS
    CV in cell size 32.23 ± 2.686 39.05 ± 3.0 <0.05 42.10 ± 4.94 <0.05 <0.05
Tomaszewski[30] 
(2014)
n 84 68 65 ECD (cell/mm2) 2503 ± 262 2297 ± 359 <0.05 2241 ± 363 <0.05 NS
age 76.7 76.5 78.2 Hexagonal % ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
    CV in cell size ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
Vannas[31] 
(1977)
n ‑‑ 7 27 ECD (cell/mm2) ‑‑ ± ‑‑ 2469.7 ± 444.4 ‑‑ 2363.6 ± 429.6 ‑‑ NS
age ‑‑ 71 68.5 Hexagonal % ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
    CV in cell size ‑‑ ± ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
Wali[32] 
(2008)
n ‑‑ 78 48 ECD (cell/mm2) ‑‑ ± ‑‑ 2483.0 ± 511.2 ‑‑ 2438.0 ± 503.4 ‑‑ NS
age ‑‑ 64.7 60.8 Hexagonal %‡ ‑‑ ± ‑‑ 66.88 ± 11.44 ‑‑ 62.91 ± 12.43 ‑‑ NS†
    Polymegathism % ‑‑ ± ‑‑ 58.14 ± 16.58 ‑‑ 59.69 ± 16.79 ‑‑ NS
Wang[33] 
(2012)
n 20 7 13 ECD (cell/mm2) 2652 ± 18 2505 ± 284 NS† 2186 ± 2 NS† NS†
age 69.5 69.1 for all 
PEX
Hexagonal % 56.1 ± 10.6 55.1 ± 19.1 NS† 5.9 ± 3.5 NS† NS†
    CV in cell size 36 ± 1.4 33.4 ± 7.8 NS† 34.7 ± 6.4 NS† NS
Wang[34] 
(1999)
n 27 18 8 ECD (cell/mm2) 2711.4 ± 307.4 2416.5 ± 271.1 <0.05 2315.9 ± 417.9 <0.05 NS
age 70.7 71.9 for all 
PEX
Hexagonal % 56.8 ± 8.7 ‑‑ ± ‑‑ ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
    CV in cell size 0.34 ± 0.05 ‑‑ ± ‑‑ ‑‑ ‑‑ ± ‑‑ ‑‑ ‑‑
Yuksel[36] 
(2016)
n 30 30 30 ECD (cell/mm2) 3073.63 ± 645.5 2592.60 ± 276.36 <0.05 2110.20 ± 620.53 <0.05 <0.05
age 64.1 65.8 66.5 Hexagonal %‡ 55.7 ± 9.72 47.77 ± 9.82 <0.05 41.47 ± 11.88 <0.05 <0.05
Polymegathism % 35.10 ± 7.6 41.9 ± 9.10 <0.05 47.96 ± 11.85 <0.05 <0.05
CNT, control; CV, coefficient of variation; ECD, endothelial cell density; PEX, pseudoexfoliation syndrome; PEXG, pseudoexfoliation syndrome with glaucoma; 
NS, not statistically significant †P values calculated fromm provided data ‡ Hexagonal % calculated with equation 1
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in a way that reduces corneal hydration and thickness. 
Alternatively, the Ocular Hypertension Treatment 
Study (OHTS) clearly showed that a reduced CCT is 
a significant risk factor in the development of POAG, 
which may simply translate to PEX patients with lower 
CCTs having a higher risk of converting to PEXG.[76] 
Yuksel et al found a statistical increase in CCT in PEXG 
patients versus PEX patients, with a potential theory 
being that reduced endothelial counts seen in PEXG 
leads to increased corneal hydration and thickness.[36] 
Future studies tracking the changes in CCT during PEX 
and PEXG progression are needed to further elucidate 
the influence pseudoexfoliation has on corneal thickness 
and hydration.
Similar and likely related to CCT changes, corneal 
biomechanics has also been shown to be altered 
in PEXG patients. Using the Ocular Response 
Analyzer (ORA) (Depew, NY, USA), Yazgan et al, 
found decreased corneal hysteresis (CH) and corneal 
resistance factor (CRF) in PEX and PEXG eyes compared 
to normal control eyes.[77] In a retrospective review, 
Ayala found reduced CH in PEXG eyes compared to 
POAG eyes.[78] This may also be a result of ECM and 
hydration alterations related to changes in keratocytes 
and disturbed endothelial counts, and could potentially 
indicate an alteration in the entire corneoscleral shell. If 
fibroblasts of the sclera are similarly reduced or altered 
in PEX patients, there may be structural alterations of the 
entire corneoscleral shell, which is significant as changes 
in the mechanics of the peripapillary sclera and lamina 
cribrosa have been shown to influence deformations of 
the optic nerve head with IOP elevations.[79,80] Moghimi 
et al found a statistically significant thinner lamina 
cribrosa in a group of nonglaucomatous PEX patients 
versus age matched controls using enhanced depth 
imaging spectral‑domain OCT.[81] Kim et al found that 
despite similar IOP and glaucoma severity between the 
two groups, the lamina cribrosa was significantly thinner 
in PEXG eyes compared to POAG eyes.[82] Furthermore, 
Kim et al found know to no difference in lamina cribrosa 
thickness between the fellow normal eye and PEXG eye 
in patients with unilateral PEXG, indicating a possible 
bilateral change in structure of the posterior globe in 
PEX patients. Braunsmann et al, using atomic force 
microscopy, found significantly reduced stiffness (lower 
Young’s modulus) of both the lamina cribrosa and 
peripapillary sclera in PEX patients compared to normal 
controls.[83] These studies suggest that PEX may be an 
independent risk factor for glaucomatous damage based 
on the mechanical function of the lamina cribrosa and 
peripapillary sclera alone.
All four studies analyzing nerve parameters in the 
cornea measured statistically significant reductions in 
nerve cell density and increased tortuosity in PEXG eyes, 
followed by PEX eyes versus normal controls. Zheng 
et al, elegantly found that these nerve changes correlated 
with decreased corneal sensitivity seen clinically,[12,13] 
indicating that corneal sensitivity may be a simple clinical 
measurement that could help the physician determine 
the extent of PEX damage to the eye. Yuksel et al was 
the only study to measure corneal nerve parameters 
separately in PEX and PEXG patients.[36] They found 
a marked reduction of approximately 50% in subbasal 
nerve density in PEXG patients versus PEX patients. 
Because topical ocular anti‑hypertensive medications 
are known to affect nerve densities,[84] they excluded 
patients on ocular medications with the exception of 
artificial tears. This data suggests corneal nerve density 
may also have potential as a quantifiable risk factor in 
determining glaucomatous progression in PEX patients, 
and may be theorized to be a more reliable parameter 
than ECD given ECD variability and changes secondary 
to intraocular surgery and inflammation.
Any conclusions gathered as a result of the literature 
review face similar limitations. The relationship between 
corneal parameters and PEX/PEXG status is not widely 
studied. We were only able to find a total of 30 studies 
spanning 1977 to 2016, and the majority of these 
were case‑control studies with limited sample sizes. 
Inter‑study comparisons are limited by the mean age 











n 30 40 ECD (cell/mm2) 2246.10 ± 251.83 2294.8 ± 235.82 NS†
age 77.2 75.9 Hexagonal % 51.03 ± 6.3 51.15 ± 6.15 NS†
CV in cell size 36.14 ± 6.89 35.93 ± 6.77 NS†
Ostern[25] 
(2012)
n 15 9 ECD (cell/mm2) 2012 ± 321 1949 ± 251 NS†
age 82.1 ‑‑ Hexagonal %‡ 51.4 ± 11.3 50.2 ± 12.5 NS†
   CV in cell size 0.419 ± 0.096 0.466 ± 0.113 NS†
Sarowa[29] 
(2016)
n 20 20 ECD (cell/mm2) 2062 ± 121.1 2257 ± 102.1 <0.05
age 70.6 64.6 Hexagonal % 48.25 ± 6.30 56.50 ± 4.807 NS
Polymegathism % 42.10 ± 4.94 36.0 ± 3.129 <0.05
CV, coefficient of variation; ECD, endothelial cell density; PEXG, pseudoexfoliation syndrome with glaucoma; POAG, primary open angle 
glaucoma; NS, not statistically significant †P values calculated form provided data ‡Hexagonal % calculated with equation 1
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of their groups, with differences up to 15 years between 
studies. Furthermore, several different devices and 
ECD analysis techniques were used to measure corneal 
parameters. It has been demonstrated that different 
endothelial cell measuring instruments and methods 
have varying correlations in terms of ECD and have 
been shown to have statistically significant differences 
in absolute ECD. The interusability of these devices is 
even more limited when measuring hexagonality and 
pleomorphism. Gasser et al found that the Topcon 
SP3000P (Oakland, NJ, USA) and Konan Noncon 
Robo SP8000 (Konan, Japan) instruments correlated 
well with ECD but the Konan device measured 
systematically higher ECD.[85] The two devices varied 
more significantly in measurements of hexagonality and 
CV. Price et al showed that among Nidek Confoscan 
4 (Padova, Italy), Tomey EM‑3000 (Phoenix, AZ, USA) 
and Konan Noncon Robo SP8000 (Konan, Japan), only 
the Robo and EM‑3000 showed automated ECD to be 
comparable to manual counts in normal eyes with even 
more divergent results in patients following Descemet 
stripping endothelial keratoplasy.[86] Finally, many 
of the reviewed studies were also limited by their 
cross‑sectional nature, as the length of time patients 
have PEX or PEXG and their severity likely play a 
significant role in corneal damage.
Despite the limitations, this review has shown a 
clear association between corneal alterations and PEX, 
which tends to be amplified in patients with PEXG. We 
therefore conclude that corneal parameters such as ECD 
and subbasal nerve cell densities may have potential 
as clinical biomarkers for pseudoexfoliation syndrome 
to assess severity of disease and to help determine 
the risk of PEX patients converting to PEXG. Future 
prospective studies will be needed to elucidate the 
association between corneal parameters and risk of PEXG 
development with a more thorough analysis utilizing a 
combination of CDR, visual field data and OCT to better 
characterize glaucomatous damage and its association 
with corneal alterations.
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